Clinical Trials Logo

Lymphoma, B-Cell, Marginal Zone clinical trials

View clinical trials related to Lymphoma, B-Cell, Marginal Zone.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 5

NCT ID: NCT00877214 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

MAINTAIN
Start date: April 1, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.

NCT ID: NCT00377195 Active, not recruiting - Clinical trials for Non-gastric Marginal Zone Lymphoma

Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma

Start date: July 8, 2007
Phase: Phase 2
Study type: Interventional

This prospective study will test the following hypotheses in patients with stage I-II low grade marginal zone (MZ) lymphoma: - Involved Field Radiotherapy will produce a complete response rate of > 90% - Radiotherapy will be associated with a locoregional progression of < 20% after 10 years - Death from MZ lymphoma will occur in < 40% of patients within 10 years of radiotherapy This study secondary objectives are: - To collect information on the prevalence of H. pylori in non-gastric MALT lymphoma - To estimate rates of acute and late toxicity of radiotherapy

NCT ID: NCT00118352 Active, not recruiting - Clinical trials for Chronic Myelomonocytic Leukemia

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who are undergoing a donor stem cell transplant for hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate, a monoclonal antibody, such as alemtuzumab, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. Giving chemotherapy or radiation therapy before or after transplant also stops the patient's immune system from rejecting the donor's bone marrow stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

NCT ID: NCT00112723 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Start date: December 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.